You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Quantification of Plasma and Bone Marrow VEGF and Angiopoietin-2 Levels in Pediatric Malignancies

Hintsala, Emilia BSc; Bono, Petri MD; Andersson, Sture MD; Kivivuori, Sanna-Maria MD

Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e318257f2a8
Original Articles
Abstract

Introduction: Data on angiogenesis in pediatric patients with malignancy are scarce. Our aim was to study angiogenic growth factors vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) in pediatric oncological patients at diagnosis and a few months after the beginning of the therapy.

Patients and Methods: Eighty-four consecutive patients with malignancy were included in this study. The levels of plasma and bone marrow VEGF and Ang2 were analyzed by enzyme-linked immunosorbent assay.

Results: The levels of VEGF were higher in patients with solid tumors than in patients with leukemias (P=0.003), whereas Ang2 concentrations showed the opposite (P=0.003). Interestingly, the plasma concentrations of both VEGF and Ang2 correlated with concentrations in the bone marrow (P<0.05). Leukemia patients with lower VEGF level and patients with higher Ang2 level at follow-up had longer event-free survival than other patients (P=0.032 and 0.053, respectively).

Discussion: The results of our study enlighten the behavior of 2 different angiogenic factors in pediatric patients with malignancy. An interesting finding was the connection between survival of pediatric leukemia patients and angiogenic factor levels a few months after the beginning of therapy. Pathophysiology and clinical applications of these findings need further studies.

Author Information

*Division of Hematology-Oncology and Stem Cell Transplantation

Division of Neonatology, Children’s Hospital

Department of Oncology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

The authors declare no conflict of interest.

Reprints: Sanna-Maria Kivivuori, MD, Division of Hematology-Oncology and Stem Cell Transplantation, Children’s Hospital, University of Helsinki and Helsinki University Central Hospital, PO Box 281, 00029 Helsinki, Finland (e-mail: sanna.kivivuori@iki.fi).

Received May 25, 2011

Accepted November 15, 2011

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.